nach oben

Erschienen in:

06.05.2020 | Original Article

Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

verfasst von: Jasna Metovic, Laura Annaratone, Alessandra Linari, Simona Osella-Abate, Chiara Musuraca, Francesca Veneziano, Chiara Vignale, Luca Bertero, Paola Cassoni, Nicola Ratto, Alessandro Comandone, Giovanni Grignani, Raimondo Piana, Mauro Papotti

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastatic tumor, with a relatively unpredictable clinical course. A retrospective series of 46 GCTB and a control group of 24 aneurysmal bone cysts (ABC) were selected with the aim of investigating the PD-L1 expression levels and immune-related gene expression profile, in correlation with clinicopathological features. PD-L1 and Ki67 were immunohistochemically tested in each case. Furthermore, comprehensive molecular analyses were carried out using NanoString technology and nCounter PanCancer Immune Profiling Panel, and the gene expression results were correlated with clinicopathological characteristics. PD-L1 expression was observed in 13/46 (28.3%) GCTB (and in 1/24, 4.2%, control ABC, only) and associated with a shorter disease free interval according to univariate analysis. Moreover, in PD-L1-positive lesions, three genes (CD27, CD6 and IL10) were significantly upregulated (p < 0.01), while two were downregulated (LCK and TLR8, showing borderline significance, p = 0.06). Interestingly, these genes can be related to maturation and immune tolerance of bone tissue microenvironment, suggesting a more immature/anergic phenotype of giant cell tumors. Our findings suggest that PD-L1 immunoreactivity may help to select GCTB patients with a higher risk of recurrence who could potentially benefit from immune checkpoint blockade.

Nur mit Berechtigung zugänglich

Cowan RW, Singh G (2013) Giant cell tumor of bone: a basic science perspective. Bone 52:238–246. https://doi.org/10.1016/j.bone.2012.10.002 CrossRefPubMed

Athanasou NA, Bansal M, Forsyth R, Reid RP, Sapi Z (2013) Giant cell tumour of bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) WHO classification of tumours of soft tissue and bone, 4th edn. IARC Press, Lyon, pp 321–324

Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E et al (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36:1–7. https://doi.org/10.1016/j.ctrv.2009.09.002 CrossRefPubMed

Werner M (2006) Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 30:484–489. https://doi.org/10.1007/s00264-006-0215-7 CrossRefPubMedPubMedCentral

Luo G, Li F, Li X, Wang ZG, Zhang B (2018) TNF-α and RANKL promote osteoclastogenesis by upregulating RANK via the NF-κB pathway. Mol Med Rep 17:6605–6611. https://doi.org/10.3892/mmr.2018.8698 CrossRefPubMedPubMedCentral

Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640–649. https://doi.org/10.1359/jbmr.2000.15.4.640 CrossRefPubMed

Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. https://doi.org/10.1038/nature01658 CrossRefPubMed

Maros ME, Schnaidt S, Balla P, Kelemen Z, Sapi Z et al (2019) In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. Bone 127:188–198. https://doi.org/10.1016/j.bone.2019.06.022 CrossRefPubMed

Kervarrec T, Collin C, Larousserie F, Bouvier C, Aubert S, Gomez-Brouchet A et al (2017) H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Mod Pathol 30:393–406. https://doi.org/10.1038/modpathol.2016.212 CrossRefPubMed

10.

Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C et al (2017) Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol 68:128–135. https://doi.org/10.1016/j.humpath.2017.08.033 CrossRefPubMed

11.

Lüke J, von Baer A, Schreiber J, Lübbehüsen C, Breining T, Mellert K et al (2017) H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 71:125–133. https://doi.org/10.1111/his.13190 CrossRefPubMed

12.

Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ et al (2015) Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res 1:113–123. https://doi.org/10.1002/cjp2.13 CrossRefPubMedPubMedCentral

13.

Montgomery C, Couch C, Emory CL, Nicholas R (2019) Giant cell tumor of bone: review of current literature, evaluation, and treatment options. J Knee Surg 32:331–336. https://doi.org/10.1055/s-0038-1675815 CrossRefPubMed

14.

Chen L, Ding XY, Wang CS, Si MJ, Du LJ, Zhang WB, Lu Y (2014) In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage. Radiol Med 119:861–870. https://doi.org/10.1007/s11547-014-0396-x CrossRefPubMed

15.

Errani C, Tsukamoto S, Leone G, Akahane M, Cevolani L, Tanzi P et al (2017) Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites. Eur J Orthop Surg Traumatol 27:813–819. https://doi.org/10.2106/JBJS.17.00057 CrossRefPubMed

16.

Lausten GS, Jensen PK, Schiødt T, Lund B (1996) Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop 20:172–176. https://doi.org/10.1007/s002640050057 CrossRefPubMed

17.

Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM et al (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18:4415–4424. https://doi.org/10.1158/1078-0432.CCR-12-0578 CrossRefPubMed

18.

Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J (2019) Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-019-03167-x CrossRefPubMed

19.

Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S et al (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901–908. https://doi.org/10.1016/S1470-2045(13)70277-8 CrossRefPubMed

20.

Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM (2018) Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 100:496–504. https://doi.org/10.2106/JBJS.17.00057 CrossRefPubMed

21.

van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H (2017) Giant cell tumour of bone in the denosumab era. Eur J Cancer 77:75–83. https://doi.org/10.1016/j.ejca.2017.02.021 CrossRefPubMed

22.

Errani C, Tsukamoto S, Mavrogenis AF (2017) How safe and effective is denosumab for bone giant cell tumour? Int Orthop 41:2397–2400. https://doi.org/10.1007/s00264-017-3536-9 CrossRefPubMed

23.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®). Bone Cancer. https://www.nccn.org/professionals/physician_gls/default.aspx#site Accessed 26 June 2019

24.

Domingues B, Lopes JM, Soares P, Pópulo H (2018) Melanoma treatment in review. Immunotargets Ther 7:35–49. https://doi.org/10.2147/ITT.S134842 CrossRefPubMedPubMedCentral

25.

Yu Y, Cui J (2018) Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol Lett 16:4105–4113. https://doi.org/10.3892/ol.2018.9219 CrossRefPubMedPubMedCentral

26.

Wang Z, Wang Z, Li B, Wang S, Chen T, Ye Z (2019) Innate immune cells: a potential and promising cell population for treating osteosarcoma. Front Immunol 10:1114. https://doi.org/10.3389/fimmu.2019.01114 CrossRefPubMedPubMedCentral

27.

Uehara T, Fujiwara T, Takeda K, Kunisada T, Ozaki T, Udono H (2015) Immunotherapy for bone and soft tissue sarcomas. Biomed Res Int 2015:820813. https://doi.org/10.1155/2015/820813 CrossRefPubMedPubMedCentral

28.

Zheng W, Xiao H, Liu H, Zhou Y (2015) Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS 123:102–107. https://doi.org/10.1111/apm.12311 CrossRefPubMed

29.

Torabi A, Amaya CN, Wians FH Jr, Bryan BA (2017) PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology 49:506–513. https://doi.org/10.1016/j.pathol.2017.05.003 CrossRefPubMed

30.

McEachron TA, Triche TJ, Sorenson L, Parham DM, Carpten JD (2018) Profiling targetable immune checkpoints in osteosarcoma. Oncoimmunology 7:e1475873. https://doi.org/10.1080/2162402X.2018.1475873 CrossRefPubMedPubMedCentral

31.

Wang J, Hu C, Wang J, Shen Y, Bao Q, He F et al (2019) Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J Immunother. https://doi.org/10.1097/CJI.0000000000000281 CrossRefPubMedPubMedCentral

32.

Rehkämper J, Steinestel K, Jeiler B, Elges S, Hekeler E, Huss S et al (2018) Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy. Oncotarget 9:30106–30114. https://doi.org/10.18632/oncotarget.25725 CrossRefPubMedPubMedCentral

33.

Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M et al (2018) Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. World J Surg Oncol 16:160. https://doi.org/10.1186/s12957-018-1459-6 CrossRefPubMedPubMedCentral

34.

Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K et al (2019) Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. Onco Targets Ther 12:2513–2518. https://doi.org/10.2147/OTT.S198421 CrossRefPubMedPubMedCentral

35.

Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM et al (2013) Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8:e82870. https://doi.org/10.1371/journal.pone.0082870 CrossRefPubMedPubMedCentral

36.

Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH et al (2016) Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16:434. https://doi.org/10.1186/s12885-016-2451-6 CrossRefPubMedPubMedCentral

37.

Xiao Y, Song JY, de Vries TJ, Fatmawati C, Parreira DB, Langenbach GE et al (2013) Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells. Proc Natl Acad Sci USA 110:12385–12390. https://doi.org/10.1073/pnas.1216082110 CrossRefPubMedPubMedCentral

38.

Bozec A, Zaiss MM (2017) T regulatory cells in bone remodelling. Curr Osteoporos Rep 15:121–125. https://doi.org/10.1007/s11914-017-0356-1 CrossRefPubMed

39.

Oliveira MI, Gonçalves CM, Pinto M, Fabre S, Santos AM, Lee SF et al (2012) CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol 42:195–205. https://doi.org/10.1002/eji.201040528 CrossRefPubMed

40.

Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K (2018) Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology 72:914–922. https://doi.org/10.1111/his.13448 CrossRefPubMed

41.

Solari F, Domenget C, Gire V, Woods C, Lazarides E, Rousset B, Jurdic P (1995) Multinucleated cells can continuously generate mononucleated cells in the absence of mitosis: a study of cells of the avian osteoclast lineage. J Cell Sci 108:3233–3241PubMed

42.

Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z et al (2016) Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5:e281. https://doi.org/10.1038/oncsis.2016.75 CrossRefPubMedPubMedCentral

43.

Janssens S, Beyaert R (2003) Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 16:637–646. https://doi.org/10.1128/CMR.16.4.637-646.2003 CrossRefPubMedPubMedCentral

44.

Schmiedel BJ, Grosse-Hovest L, Salih HR (2013) A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL? Oncoimmunology 2:e23850. https://doi.org/10.4161/onci.23850 CrossRefPubMedPubMedCentral

45.

Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC et al (2006) Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115–1126. https://doi.org/10.1093/intimm/dxl046 CrossRefPubMed

46.

Huang L, Zhu P, Xia P, Fan Z (2016) WASH has a critical role in NK cell cytotoxicity through Lck-mediated phosphorylation. Cell Death Dis 7:e2301. https://doi.org/10.1038/cddis.2016.212 CrossRefPubMedPubMedCentral

47.

Francisconi CF, Vieira AE, Azevedo MCS, Tabanez AP, Fonseca AC, Trombone APF et al (2018) RANKL triggers treg-mediated immunoregulation in inflammatory osteolysis. J Dent Res 97:917–927. https://doi.org/10.1177/0022034518759302 CrossRefPubMedPubMedCentral

48.

Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E et al (2017) Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 76:118–124. https://doi.org/10.1016/j.ejca.2017.01.028 CrossRefPubMed

49.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930–2940. https://doi.org/10.1172/JCI91190 CrossRefPubMedPubMedCentral

50.

Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I et al (2018) Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 6:63. https://doi.org/10.1186/s40425-018-0367-1 CrossRefPubMedPubMedCentral

51.

Klein S, Mauch C, Wagener-Ryczek S, Schoemmel M, Buettner R, Quaas A et al (2019) Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunol Immunother 68:973–982. https://doi.org/10.1007/s00262-019-02339-3 CrossRefPubMed

Titel: Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone
verfasst von: Jasna Metovic
Laura Annaratone
Alessandra Linari
Simona Osella-Abate
Chiara Musuraca
Francesca Veneziano
Chiara Vignale
Luca Bertero
Paola Cassoni
Nicola Ratto
Alessandro Comandone
Giovanni Grignani
Raimondo Piana
Mauro Papotti
Publikationsdatum: 06.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02594-9

Springer Medizin

Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy

Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells

Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study

A gene expression-based immune signature for lung adenocarcinoma prognosis

Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie